Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home
  • Log in
  • My Cart

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
Research Article

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2

Efrat Gabai-Kapara, Amnon Lahad, Bella Kaufman, Eitan Friedman, Shlomo Segev, Paul Renbaum, Rachel Beeri, Moran Gal, Julia Grinshpun-Cohen, Karen Djemal, Jessica B. Mandell, Ming K. Lee, Uziel Beller, Raphael Catane, Mary-Claire King, and Ephrat Levy-Lahad
  1. aMedical Genetics Institute, Shaare Zedek Medical Center, Jerusalem 91031, Israel;
  2. bFaculty of Medicine, Hebrew University Medical School, Jerusalem 91120, Israel;
  3. cDepartment of Family Medicine, Clalit Health Services, Jerusalem 91120, Israel;
  4. dInstitute of Oncology, Sheba Medical Center, Tel Hashomer 52621, Israel;
  5. eSusanne Levy Gertner Oncogenetics Unit, Sheba Medical Center, Tel Hashomer 52621, Israel;
  6. fSackler School of Medicine, Tel Aviv University, Tel-Aviv 69978, Israel;
  7. gInstitute of Medical Screening, Sheba Medical Center, Tel Hashomer 52621, Israel;
  8. hTerem Family Medical Center, Jerusalem 92345, Israel;
  9. iDepartments of Medicine and Genome Sciences, University of Washington, Seattle, WA 98195; and
  10. jDepartment of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem 91031, Israel

See allHide authors and affiliations

PNAS first published September 5, 2014; https://doi.org/10.1073/pnas.1415979111
Efrat Gabai-Kapara
aMedical Genetics Institute, Shaare Zedek Medical Center, Jerusalem 91031, Israel;
bFaculty of Medicine, Hebrew University Medical School, Jerusalem 91120, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amnon Lahad
bFaculty of Medicine, Hebrew University Medical School, Jerusalem 91120, Israel;
cDepartment of Family Medicine, Clalit Health Services, Jerusalem 91120, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bella Kaufman
dInstitute of Oncology, Sheba Medical Center, Tel Hashomer 52621, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eitan Friedman
eSusanne Levy Gertner Oncogenetics Unit, Sheba Medical Center, Tel Hashomer 52621, Israel;
fSackler School of Medicine, Tel Aviv University, Tel-Aviv 69978, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shlomo Segev
gInstitute of Medical Screening, Sheba Medical Center, Tel Hashomer 52621, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Renbaum
aMedical Genetics Institute, Shaare Zedek Medical Center, Jerusalem 91031, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Beeri
aMedical Genetics Institute, Shaare Zedek Medical Center, Jerusalem 91031, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Moran Gal
aMedical Genetics Institute, Shaare Zedek Medical Center, Jerusalem 91031, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Grinshpun-Cohen
aMedical Genetics Institute, Shaare Zedek Medical Center, Jerusalem 91031, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Djemal
hTerem Family Medical Center, Jerusalem 92345, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica B. Mandell
iDepartments of Medicine and Genome Sciences, University of Washington, Seattle, WA 98195; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming K. Lee
iDepartments of Medicine and Genome Sciences, University of Washington, Seattle, WA 98195; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uziel Beller
jDepartment of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem 91031, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raphael Catane
dInstitute of Oncology, Sheba Medical Center, Tel Hashomer 52621, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary-Claire King
iDepartments of Medicine and Genome Sciences, University of Washington, Seattle, WA 98195; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mcking@u.washington.edu lahad@szmc.org.il
Ephrat Levy-Lahad
aMedical Genetics Institute, Shaare Zedek Medical Center, Jerusalem 91031, Israel;
bFaculty of Medicine, Hebrew University Medical School, Jerusalem 91120, Israel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mcking@u.washington.edu lahad@szmc.org.il
  1. Contributed by Mary-Claire King, August 19, 2014 (sent for review July 17, 2014; reviewed by Anne M. Bowcock and Karl Skorecki)

  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

Significance

Inherited mutations in the tumor suppressor genes BRCA1 and BRCA2 predispose to very high risks of breast and ovarian cancer. For carriers of these mutations, risk-reducing surgery significantly reduces morbidity and mortality. General population screening for BRCA1 and BRCA2 mutations in young adult women could be feasible if accurate estimates of cancer risk for mutation carriers could be obtained. We determined that risks of breast and ovarian cancer for BRCA1 and BRCA2 mutation carriers ascertained from the general population are as high as for mutation carriers ascertained through personal or family history of cancer. General screening of BRCA1 and BRCA2 would identify many carriers who are currently not evaluated and could serve as a model for population screening for genetic predisposition to cancer.

Abstract

In the Ashkenazi Jewish (AJ) population of Israel, 11% of breast cancer and 40% of ovarian cancer are due to three inherited founder mutations in the cancer predisposition genes BRCA1 and BRCA2. For carriers of these mutations, risk-reducing salpingo-oophorectomy significantly reduces morbidity and mortality. Population screening for these mutations among AJ women may be justifiable if accurate estimates of cancer risk for mutation carriers can be obtained. We therefore undertook to determine risks of breast and ovarian cancer for BRCA1 and BRCA2 mutation carriers ascertained irrespective of personal or family history of cancer. Families harboring mutations in BRCA1 or BRCA2 were ascertained by identifying mutation carriers among healthy AJ males recruited from health screening centers and outpatient clinics. Female relatives of the carriers were then enrolled and genotyped. Among the female relatives with BRCA1 or BRCA2 mutations, cumulative risk of developing either breast or ovarian cancer by age 60 and 80, respectively, were 0.60 (± 0.07) and 0.83 (± 0.07) for BRCA1 carriers and 0.33 (± 0.09) and 0.76 (± 0.13) for BRCA2 carriers. Risks were higher in recent vs. earlier birth cohorts (P = 0.006). High cancer risks in BRCA1 or BRCA2 mutation carriers identified through healthy males provide an evidence base for initiating a general screening program in the AJ population. General screening would identify many carriers who are not evaluated by genetic testing based on family history criteria. Such a program could serve as a model to investigate implementation and outcomes of population screening for genetic predisposition to cancer in other populations.

  • genomics

Footnotes

  • ↵1E.G.-K. and A.L. contributed equally to this work.

  • ↵2To whom correspondence may be addressed. Email: mcking{at}u.washington.edu or lahad{at}szmc.org.il.
  • Author contributions: E.G.-K., A.L., M.-C.K., and E.L.-L. designed research; E.G.-K., A.L., B.K., E.F., S.S., P.R., R.B., M.G., J.G.-C., K.D., J.B.M., U.B., R.C., M.-C.K., and E.L.-L. performed research; E.G.-K., A.L., P.R., M.K.L., M.-C.K., and E.L.-L. analyzed data; A.L., M.-C.K., and E.L.-L. wrote the paper; and B.K., E.F., S.S., K.D., and U.B. referred participants.

  • Reviewers: A.M.B., Imperial College London; and K.S., Technion – Israel Institute of Technology.

  • The authors declare no conflict of interest.

  • This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1415979111/-/DCSupplemental.

Next
Back to top
Article Alerts
Email Article

Thank you for your interest in spreading the word on PNAS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2
(Your Name) has sent you a message from PNAS
(Your Name) thought you would like to see the PNAS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
BRCA1 and BRCA2 breast and ovarian cancer risks
Efrat Gabai-Kapara, Amnon Lahad, Bella Kaufman, Eitan Friedman, Shlomo Segev, Paul Renbaum, Rachel Beeri, Moran Gal, Julia Grinshpun-Cohen, Karen Djemal, Jessica B. Mandell, Ming K. Lee, Uziel Beller, Raphael Catane, Mary-Claire King, Ephrat Levy-Lahad
Proceedings of the National Academy of Sciences Sep 2014, 201415979; DOI: 10.1073/pnas.1415979111

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
BRCA1 and BRCA2 breast and ovarian cancer risks
Efrat Gabai-Kapara, Amnon Lahad, Bella Kaufman, Eitan Friedman, Shlomo Segev, Paul Renbaum, Rachel Beeri, Moran Gal, Julia Grinshpun-Cohen, Karen Djemal, Jessica B. Mandell, Ming K. Lee, Uziel Beller, Raphael Catane, Mary-Claire King, Ephrat Levy-Lahad
Proceedings of the National Academy of Sciences Sep 2014, 201415979; DOI: 10.1073/pnas.1415979111
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Mendeley logo Mendeley
Proceedings of the National Academy of Sciences: 118 (9)
Current Issue

Submit

Sign up for Article Alerts

Jump to section

  • Article
  • Figures & SI
  • Info & Metrics
  • PDF

You May Also be Interested in

Setting sun over a sun-baked dirt landscape
Core Concept: Popular integrated assessment climate policy models have key caveats
Better explicating the strengths and shortcomings of these models will help refine projections and improve transparency in the years ahead.
Image credit: Witsawat.S.
Model of the Amazon forest
News Feature: A sea in the Amazon
Did the Caribbean sweep into the western Amazon millions of years ago, shaping the region’s rich biodiversity?
Image credit: Tacio Cordeiro Bicudo (University of São Paulo, São Paulo, Brazil), Victor Sacek (University of São Paulo, São Paulo, Brazil), and Lucy Reading-Ikkanda (artist).
Syrian archaeological site
Journal Club: In Mesopotamia, early cities may have faltered before climate-driven collapse
Settlements 4,200 years ago may have suffered from overpopulation before drought and lower temperatures ultimately made them unsustainable.
Image credit: Andrea Ricci.
Steamboat Geyser eruption.
Eruption of Steamboat Geyser
Mara Reed and Michael Manga explore why Yellowstone's Steamboat Geyser resumed erupting in 2018.
Listen
Past PodcastsSubscribe
Birds nestling on tree branches
Parent–offspring conflict in songbird fledging
Some songbird parents might improve their own fitness by manipulating their offspring into leaving the nest early, at the cost of fledgling survival, a study finds.
Image credit: Gil Eckrich (photographer).

Similar Articles

Site Logo
Powered by HighWire
  • Submit Manuscript
  • Twitter
  • Facebook
  • RSS Feeds
  • Email Alerts

Articles

  • Current Issue
  • Special Feature Articles – Most Recent
  • List of Issues

PNAS Portals

  • Anthropology
  • Chemistry
  • Classics
  • Front Matter
  • Physics
  • Sustainability Science
  • Teaching Resources

Information

  • Authors
  • Editorial Board
  • Reviewers
  • Subscribers
  • Librarians
  • Press
  • Site Map
  • PNAS Updates
  • FAQs
  • Accessibility Statement
  • Rights & Permissions
  • About
  • Contact

Feedback    Privacy/Legal

Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490